Exozymes (EXOZ) Change in Account Payables (2023 - 2025)
Exozymes (EXOZ) posted quarterly Change in Account Payables of -$5755.0 for Q4 2025, up 99.86% year-over-year from -$2879.5 in Q4 2024, and down 150.35% quarter-over-quarter from $11431.0 in Q3 2025.
Exozymes (EXOZ) Change in Account Payables (2023 - 2025) Analysis & Trends
Exozymes (EXOZ) has reported Change in Account Payables for 3 consecutive years, with -$5755.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 99.86% year-over-year to -$5755.0; the TTM figure through Dec 2025 stood at -$4.3 million (down 2.32% YoY), while the FY2025 annual figure was -$26533.0, up 99.37% from the prior year.
- Change in Account Payables eased to -$5755.0 in Q4 2025 per EXOZ's latest filing, from $11431.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.3 million in Q1 2024 and bottomed at -$4.2 million in Q4 2024.
- Historically, Change in Account Payables has averaged -$603376.3 across 3 years, with a median of -$5755.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Account Payables sank 31063.83% — and 2025, when it soared 111.26%.
- Exozymes' Change in Account Payables stood at $13712.0 in 2023, then tumbled by 31063.83% to -$4.2 million in 2024, then jumped by 99.86% to -$5755.0 in 2025.
- Business Quant data shows EXOZ's Change in Account Payables at -$5755.0 in Q4 2025, $11431.0 in Q3 2025, and -$4.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,755.00 |
| Dec 31, 2025 | -5,755.00 |
| Sep 30, 2025 | 11,431.00 |
| Sep 30, 2025 | 11,431.00 |
| Dec 31, 2024 | -4.25 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Sep 30, 2024 | -101,492.00 |
| Sep 30, 2024 | -101,492.00 |
| Jun 30, 2024 | -1.22 Mn |
| Jun 30, 2024 | -1.22 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 13,712.00 |
| Dec 31, 2023 | 13,712.00 |